Parathyroid Hormone (1-34) Augments Angiopoietin-1 Expression in Human Osteoblast-like Cells

Abstract

Parathyroid hormone (PTH) is a major regulatory factor in skeletal physiology. However, the molecular mechanism underlying the effects of PTH on bones has yet to be elucidated in detail. Recently, some reports have demonstrated the crucial role of bone vasculature with regard to bone density. Angiopoietin-1 (Ang-1), along with VEGF, has been established as a primary angiogenic regulatory agent. In this study, we have attempted to characterize the effects of PTH (1-34) on Ang-1 expression and signaling molecules, employing primary-cultured human osteoblast-like cells. Quiescent osteoblasts were exposed to PTH (1-34), after which Ang-1 expression was determined at the mRNA and protein levels. Reverse transcription-polymerase chain reaction (RT-PCR) analyses indicated that Ang-1 mRNA expression increased as the result of PTH (1-34) treatment. The expression of the Ang-1 protein was also augmented as the result of treatment with PTH (1-34). An adenylyl cyclase activator, forskolin, was shown to induce Ang-1 mRNA expression, whereas the protein kinase A inhibitor, H-89, blocked the PTH (1-34)-mediated expression of Ang-1 mRNA. These findings indicate that PTH (1-34)-mediated Ang-1 expression involves adenylyl cyclase-protein kinase A dependent signaling. Our observations also show that Ang-1 may perform a crucial role in the effects of PTH (1-34) on bones, possibly involving alterations in bone vasculature.

Key words

Osteoblasts - parathyroid hormone (1-34) - angiopoietin-1

References

• 1 Burkhardt R, Kettner G, Bohm W, Schmidmeier M, Schlag R, Frisch B, Mallmann B, Eisenmenger W, Gilg T. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study.  Bone. 1987;  8 157-164
• 2 Cosman F, Lindsay R. Therapeutic potential of parathyroid hormone.  Curr Osteoporos Rep. 2004;  2 5-11
• 3 Deckers MM, Karperien M, van der Bent C, Yamashita T, Papapoulos SE, Lowik CW. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation.  Endocrinology. 2000;  141 1667-1674
• 4 Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions.  Circ Res. 2000;  87 603-607
• 5 Gardella TJ, Juppner H. Molecular properties of the PTH/PTHrP receptor.  Trends Endocrinol Metab. 2001;  12 210-217
• 6 Griffith JF, Yeung DK, Antonio GE, Lee FK, Hong AW, Wong SY, Lau EM, Leung PC. Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy.  Radiology. 2005;  236 945-951
• 7 Habener JF, Rosenblatt M, Potts Jr JT. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism.  Physiol Rev. 1984;  64 985-1053
• 8 Harada S, Nagy JA, Sullivan KA, Thomas KA, Endo N, Rodan GA, Rodan SB. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts.  J Clin Invest. 1994;  93 2490-2496
• 9 Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells.  J Clin Invest. 1997;  99 2961-2970
• 10 Juppner H, Gardellar TJ, Brown EM, Kronenberg HM, Potts JT. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development. In: Degroot LJ, Jameson JL (eds). Endocrinology. 5th edn. Philadelphia: Elsevier Saunders 2006 2: 1390-1391
• 11 Kim I, Kim HG, Moon SO, Chae SW, So JN, Koh KN, Ahn BC, Koh GY. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion.  Circ Res. 2000;  86 952-959
• 12 Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Angiopoietin-1 is an apoptosis survival factor for endothelial cells.  FEBS Lett. 1999;  448 249-253
• 13 Laroche M, Ludot I, Thiechart M, Arlet J, Pieraggi M, Chiron P, Moulinier L, Cantagrel A, Puget J, Utheza G. Study of the intraosseous vessels of the femoral head in patients with fractures of the femoral neck or osteoarthritis of the hip.  Osteoporos Int. 1995;  5 213-217
• 14 Lorenzo JA, Sousa S, Quinton J. Forskolin has both stimulatory and inhibitory effects on bone resorption in fetal rat long bone cultures.  J Bone Miner Res. 1986;  1 313-317
• 15 Lorraine I, Hunter H. Primary hyperparathyroidism and hyperparathyroid bone disease. In: Marcus R, Feldman D, Kelsey J (eds). Osteoporosis. 2nd edn. San Diego: Academic press 2001 2: 259-260
• 16 Miao D, He B, Karaplis AC, Goltzman D. Parathyroid hormone is essential for normal fetal bone formation.  J Clin Invest. 2002;  109 1173-1182
• 17 Nannmark U, Buch F, Albrektsson T. Influence of direct currents on bone vascular supply.  Scand J Plast Reconstr Surg Hand Surg. 1988;  22 113-115
• 18 Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.  N Engl J Med. 2001;  344 1434-1441
• 19 Nissenson RA. Parathyroid hormone and parathyroid hormone-related protein. In: Marcus R, Feldman D, Kelsey J (eds). Osteoporosis. 2nd edn. San Diego: Academic press 2001 1: 223-226
• 20 Probst A, Spiegel HU. Cellular mechanisms of bone repair.  J Invest Surg. 1997;  10 77-86
• 21 Reeve J, Arlot M, Wootton R, Edouard C, Tellez M, Hesp R, Green JR, Meunier PJ. Skeletal blood flow, iliac histomorphometry, and strontium kinetics in osteoporosis: a relationship between blood flow and corrected apposition rate.  J Clin Endocrinol Metab. 1988;  66 1124-1131
• 22 Rixon RH, Whitfield JF, Gagnon L, Isaacs RJ, Maclean S, Chakravarthy B, Durkin JP, Neugebauer W, Ross V, Sung W. Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase.  J Bone Miner Res. 1994;  9 1179-1189
• 23 Robey PG, Termine JD. Human bone cells in vitro.  Calcif Tissue Int. 1985;  37 453-460
• 24 Schlaeppi J-M, Gutzwiller S, Finkenzeller G, Fournier B. 1,25-dihydroxyvitamin D3 induces the expression of vascular endothelial growth factor in osteoblastic cells.  Endocrinol Res. 1997;  23 213-229
• 25 Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.  Cell. 1996;  87 1171-1180
• 26 Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.  Science. 1999;  286 2511-2514
• 27 Trueta J, Buhr AJ. The vascular contribution to osteogenesis. v. the vasculature supplying the epiphysial cartilage in rachitic rats.  J Bone Joint Surg Br. 1963;  45 572-581
• 28 Valable S, Bellail A, Lesne S, Liot G, Mackenzie ET, Vivien D, Bernaudin M, Petit E. Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis.  FASEB J. 2003;  17 443-445
• 29 Wang DS, Yamazaki K, Nohtomi K, Shizume K, Ohsumi K, Shibuya M, Demura H, Sato K. Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells.  J Bone Miner Res. 1996;  11 472-479

Correspondence